In the last trading session, 1.38 million Monte Rosa Therapeutics Inc (NASDAQ:GLUE) shares changed hands as the company’s beta touched 1.35. With the company’s per share price at $9.13 changed hands at -$0.88 or -8.79% during last session, the market valuation stood at $560.92M. GLUE’s last price was a discount, traded about -35.82% off its 52-week high of $12.40. The share price had its 52-week low at $2.91, which suggests the last value was 68.13% up since then. When we look at Monte Rosa Therapeutics Inc’s average trading volume, we note the 10-day average is 1.96 million shares, with the 3-month average coming to 2.08 million.
Analysts gave the Monte Rosa Therapeutics Inc (GLUE) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended GLUE as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Monte Rosa Therapeutics Inc’s EPS for the current quarter is expected to be -0.46.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Monte Rosa Therapeutics Inc (NASDAQ:GLUE) trade information
Instantly GLUE was in red as seen at the end of in last trading. With action -2.46%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 61.59%, with the 5-day performance at -2.46% in the red. However, in the 30-day time frame, Monte Rosa Therapeutics Inc (NASDAQ:GLUE) is 85.57% up. Looking at the short shares, we see there were 5.23 million shares sold at short interest cover period of 8.36 days.
Monte Rosa Therapeutics Inc (GLUE) estimates and forecasts
Data shows that the Monte Rosa Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 82.60% over the past 6 months, a 57.79% in annual growth rate that is considerably higher than the industry average of 17.10%.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 3.98M. 2 analysts are of the opinion that Monte Rosa Therapeutics Inc’s revenue for the current quarter will be 2.5M. The estimates for the next quarter sales put growth at 135.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -96.71%. The 2024 estimates are for Monte Rosa Therapeutics Inc earnings to increase by 61.76%.
GLUE Dividends
Monte Rosa Therapeutics Inc is expected to release its next quarterly earnings report in December.
Monte Rosa Therapeutics Inc (NASDAQ:GLUE)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.70% of Monte Rosa Therapeutics Inc shares while 84.09% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 84.69%. There are 84.09% institutions holding the Monte Rosa Therapeutics Inc stock share, with NEA MANAGEMENT COMPANY, LLC the top institutional holder. As of 2024-06-30, the company held 12.7872% of the shares, roughly 7.69 million GLUE shares worth $28.77 million.
PRICE T ROWE ASSOCIATES INC /MD/ holds the second largest percentage of outstanding shares, with 9.9368% or 5.98 million shares worth $22.36 million as of 2024-06-30.
